MichaelEthanCarneyMD

Obstetrics & Gynecology • Honolulu, HI

Gynecologic Oncology

Professor and Division Director University of Hawaii

Join to view full profile

Dr. Carney is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Carney's full profile

Already have an account?

Office
1319 Punahou St
Suite 640
Honolulu, HI 96826
Phone+1 808-983-6090

Fax+1 808-983-6096

Education & Training

Duke University HospitalFellowship, Gynecologic Oncology, 1996 - 1999
Duke University HospitalResidency, Obstetrics and Gynecology, 1990 - 1994
Loyola University Chicago Stritch School of MedicineClass of 1990

Certifications & Licensure

HI State Medical License 2001 - 2026
UT State Medical License 1999 - 2008
NC State Medical License 1994 - 2004
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Best Doctors Castle and Connelly 2007-present
Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
Recruiting
Phase 3
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09
Completed
Phase 3
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Start of enrollment: 2014 Feb 14
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

3677 citations
Integrated genomic characterization of endometrial carcinoma
Gad Getz, Stacey Gabriel, Kristian Cibulskis, Eric S. Lander, Andrey Sivachenko
Nature. 2013-05-02
155 citations
Reproductive Factors and Epithelial Ovarian Cancer Risk by Histologic Type:A Multiethnic Case-Control Study
Ko-Hui Tung, Marc T. Goodman, Anna H. Wu, Katharine McDuffie, Lynne R. Wilkens
American Journal of Epidemiology. 2003-10-01
248 citations
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Franz X. Schaub, Varsha Dhankani, Ashton C. Berger, Mihir Trivedi, Anne B. Richardson
Cell Systems. 2018-03-28

Press Mentions

New Gynecologic Oncology Services Being Offered in HiloMay 3rd, 2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Fellow
SGO
Member
American College of Obstetricians and Gynecologists
Member
Alpha Omega Alpha Honor Medical Society - AOA
Member
ICGS
Member
Hawaii Society of Clinical Oncology
Member